Acura Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the research, development and commercialization of technologies and products intended to address medication abuse and misuse. The Company has discovered and developed two proprietary technologies. The Company’s Aversion Technology is a mixture of inactive ingredients incorporated into pharmaceutical tablets and capsules intended to address some common methods of product tampering associated with opioid abuse. The Company’s Impede Technology is a combination of inactive ingredients preventing the extraction of pseudoephedrine from tablets and disrupts the direct conversion of pseudoephedrine from tablets into methamphetamine. The Company has seven additional opioid products utilizing Aversion in various stages of development. The Company markets products using telemarketing, direct mail, and online and journal advertising.